Live webinar - Contemporary therapeutic approaches for resistant hypertension
Despite major advances in our understanding of hypertension and the wide variety of available lifestyle modifications and medications, many of our patients remain uncontrolled. Once non-adherence to therapy and secondary causes of hypertension have been ruled out, where should we turn next?
Join Professor Markus Schlaich in this practical webinar on the latest in hypertension management, from ambulatory blood pressure monitoring to combination therapies, and the emerging role of interventional approaches such as renal denervation that have the potential to become the ‘third pillar’ of hypertension management.
Date and time: Thursday 18 November 2021, 7:00pm - 8:30pm AEDT
Duration: 1.5 hours
Professional development: 3 RACGP CPD points/2 ACRRM PDP hours
By completing this learning activity, participants will be able to:
- Evaluate clinical and lifestyle factors that may result in uncontrolled hypertension.
- Investigate factors contributing to elevated blood pressure through identification of secondary causes and the application of ambulatory blood pressure monitoring.
- Evaluate the role of single-pill combination therapies and complementary pharmacotherapies in improving patient outcomes and quality of life.
- Develop a comprehensive model of care for resistant hypertension based on latest evidence, including novel treatment methods such as renal denervation.
Presented by Professor Markus Schlaich
Dobney Chair in Clinical Research
Dobney Hypertension Centre
School of Medicine - Royal Perth Hospital Unit
Royal Perth Hospital Medical Research Foundation
The University of Western Australia
Professor Schlaich is a renal physician and a European Society of Hypertension (ESH) accredited hypertension specialist with a strong background in clinical research. His main scientific interests focus on pathophysiologic aspects of hypertension, involvement of the kidneys, and hypertension mediated organ damage. Professor Schlaich has a specific interest in treatment modalities targeting the sympathetic nervous system and has contributed to the development of renal denervation and carotid body modulation as alternative therapeutic approaches for hypertension, and more recently hepatic denervation for modulation of glucose metabolism. He has authored more than 400 articles and book chapters in peer reviewed journals and has received several research prizes and awards including the ESH Björn Folkow Award for outstanding contribution to original research in hypertension. He currently serves as President of the High Blood Pressure Research Council of Australia and is on the Scientific Council of the International Society of Hypertension for which he previously served as treasurer. He is a founding member of the European Society of Hypertension Working Group on Interventional Treatment of Hypertension. He serves on the Editorial Board of Hypertension, Journal of Hypertension, and Current Hypertension Reports. He has been involved in guideline development both nationally (2016 Heart Foundation Guidelines) and internationally (2020 ISH Global Hypertension Practice Guidelines). He is passionate about educating the next generation of clinician researchers and has received the inaugural Mentorship Award from the Royal Perth Hospital.
This activity is sponsored by Medtronic.